Covid-19 vaccine effectiveness studies in Nigeria: Quo vadis?
Akande, Oluwatosin Wuraola
Igumbor, Ehimario Uche
Elimian, Kelly Osezele
MetadataShow full item record
The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set .